EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Atypical Hemolytic Uremic Syndrome Triggered by COVID ‐19 Infection in a Pediatric Patient With CD46 Mutation

Parsa Lorestani iD, Parisa Maleki Dana iD, Mohamad Reza Tohidi iD

Clinical Case Reports · 2025-03 · 13 (3)

DOI: 10.1002/ccr3.70308 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Case Reports, online erschienen am 14.03.2025. Verfasst von Parsa Lorestani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Students Research Committee Kermanshah University of Medical Sciences Kermanshah Iran. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) that is considered life‐threatening and caused by dysregulation of the complement system. Here, we report a previously healthy 8‐year‐old boy who presented with features of aHUS 1 week after viral symptoms during the COVID‐19 pandemic. The patient was initially admitted for viral symptoms, pallor, edema, and urine color changes. Laboratory tests revealed anemia, thrombocytopenia, and elevated levels of creatinine and blood urea nitrogen (BUN). Despite fluid and electrolyte management, he developed pulmonary edema, necessitating hemodialysis and plasmapheresis. Genetic testing identified a homozygous pathogenic mutation in the CD46 gene, which encodes membrane cofactor protein (MCP). While initially responding to treatment, the patient experienced a relapse, requiring further interventions including eculizumab therapy. This case highlights the potential of COVID‐19 to trigger complement‐mediated TMA and emphasizes the importance of prompt diagnosis, genetic assessment, and targeted complement inhibition in managing aHUS.

Schlagwörter

Stichwörter der Autor:innen

CD46 mutationCOVID‐19atypical hemolytic uremic syndromeeculizumabthrombotic microangiopathy

Autor:innen und Institutionen

  • Students Research Committee Kermanshah University of Medical Sciences Kermanshah Iran.
  • Research Center for Biochemistry and Nutrition in Metabolic Diseases Kashan University of Medical Sciences Kashan Iran.
  • Department of Pediatric Nephrology, Urology and Nephrology Research Center Kermanshah University of Medical Sciences Kermanshah Iran.

ORCID-Profile: Parsa Lorestani, Parisa Maleki Dana, Mohamad Reza Tohidi

Zitieren

APA

Lorestani, P., Maleki Dana, P., & Tohidi, M. R. (2025). Atypical Hemolytic Uremic Syndrome Triggered by COVID ‐19 Infection in a Pediatric Patient With CD46 Mutation. Clinical Case Reports, 13(3). https://doi.org/10.1002/ccr3.70308

Vancouver

Lorestani P, Maleki Dana P, Tohidi MR. Atypical Hemolytic Uremic Syndrome Triggered by COVID ‐19 Infection in a Pediatric Patient With CD46 Mutation. Clinical Case Reports. 2025;13(3). doi:10.1002/ccr3.70308

BibTeX
@article{Lorestani2025,
  author = {Lorestani, Parsa and Maleki Dana, Parisa and Tohidi, Mohamad Reza},
  title = {Atypical Hemolytic Uremic Syndrome Triggered by COVID ‐19 Infection in a Pediatric Patient With CD46 Mutation},
  journal = {Clinical Case Reports},
  year = {2025},
  volume = {13},
  number = {3},
  doi = {10.1002/ccr3.70308}
}
Kostenlos starten →